HIV Treatment
CROI 2017: Several New Candidates in HIV Drug Pipeline Discussed at Conference
- Details
- Category: Experimental HIV Drugs
- Published on Saturday, 04 March 2017 00:00
- Written by Liz Highleyman
This year's Conference on Retroviruses and Opportunistic Infections (CROI), held last month in Seattle, included presentations on several new investigational antiretroviral drugs in development, reflecting a more robust pipeline than we have seen in recent years.
CROI 2017: Timothy Brown, the Berlin Patient, Celebrates a Decade Cured of HIV
- Details
- Category: Search for a Cure
- Published on Tuesday, 28 February 2017 00:00
- Written by Liz Highleyman
Participants at a Community HIV Cure Research Workshop on February 12, in advance of the Conference on Retroviruses and Opportunistic Infections in Seattle, held a "birthday" party for Timothy Ray Brown -- formerly known as the Berlin Patient -- to celebrate 10 years since the bone marrow transplant that would lead to the only known cure for HIV.
CROI 2017: Time with Transmissible HIV Viral Load Has Fallen By Three-Quarters Since 2000
- Details
- Category: HIV Treatment
- Published on Tuesday, 28 February 2017 00:00
- Written by Gus Cairns
A study by the Centers for Disease Control and Prevention (CDC) presented at the recent Conference on Retroviruses and Opportunistic Infections in Seattle found that the proportion of time people with HIV in the U.S. spend in care but not virally suppressed has fallen from 40% to 10% in the last 15 years. The study also found that young people, black people, and people with public rather than private health coverage spent less time with viral load below 1500 copies/mL, the World Health Organization (WHO) threshold for HIV transmission.
CROI 2017: Bone Marrow Transplant Patient Off ART for 288 Days Without HIV Rebound
- Details
- Category: Search for a Cure
- Published on Tuesday, 28 February 2017 00:00
- Written by Liz Highleyman
A HIV-positive bone marrow transplant recipient at the Mayo Clinic experienced prolonged viral remission lasting nearly 10 months -- longer than the so-called Boston patients -- after interrupting antiretroviral therapy (ART), according to a report at the Conference on Retroviruses and Opportunistic Infections this month in Seattle. Although his viral load eventually rebounded, his HIV reservoirs appeared to be reduced.
CROI 2017: Treatment-as-Prevention Study Sees Substantial Drug Resistance, but No Impact on HIV Therapy
- Details
- Category: HIV Treatment
- Published on Tuesday, 28 February 2017 00:00
- Written by Gus Cairns
A study of the prevalence of transmitted drug resistance among participants in the ANRS 12249 trial of treatment as prevention, has found that a substantial minority of participants had HIV with drug resistance mutations. However, there was no evidence that pre-existing drug resistance had any impact on the success of treatment, according to a report at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.
More Articles...
- CROI 2017: New HIV Capsid Inhibitors Show High Potency and Prolonged Activity in Early Studies
- CROI 2017: Monoclonal Antibodies Show Promise for HIV+ People with Few Treatment Options
- CROI 2017: New NNRTI Doravirine Shows Good Efficacy in Phase 3 Study
- CROI 2017: Spanish HIV Vaccine Induces Control Off ART in Nearly 40% of Recipients
Web Design and Development by